Trastuzumab Deruxtecan in Advanced Breast Cancer

Wenjin Yin

Status: Enrolling

Conditions: Advanced Breast Cancer

Treatments: Drug: Trastuzumab deruxtecan

Study type: Observational

Funder types: Other

Identifiers

NCT07180264

LY2025-137-B

Details and patient eligibility

About

To evaluate the efficacy and safety of trastuzumab deruxtecan in advanced breast cancer patients.

Enrollment: 118 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged ≥18 and older
• Breast cancer patients meeting current guideline recommendations and planning to receive trastuzumab deruxtecan
• ECOG 0-1

Exclusion criteria

• During pregnancy and lactation

Trial design

118 participants in 1 patient group

Trastuzumab deruxtecan

Description:

Trastuzumab deruxtecan, recommended dose 5.4mg/kg, every 21 days

Treatment:

Drug: Trastuzumab deruxtecan